JPRN-jRCT2080220732未知2 期
A Phase 2 Randomised, Double-Blind, Parallel Group, 4-Week Treatment, Adaptive Dose Finding, Multi-Centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee
试验速览
- 阶段
- 2 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Patients with OA of the knee
排除标准
- •- A current diagnosis of another form of arthritis, in addition to OA
- •- History, and/or presence of somatic disease, which may interfere with the objectives
研究者
相似试验
招募中
2 期
A phase II Clinical trial of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active ulcerative colitisCTRI/2022/11/047054Biocon Limited
进行中（未招募）
不适用
A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-024000-10-DEBiogen Idec Limited300
进行中（未招募）
不适用
A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple SclerosisEUCTR2010-024000-10-ESBiogen Idec Limited300
进行中（未招募）
不适用
A Study to Evaluate the Effect of Different Doses of TYSABRI on Safety and Efficacy in Relapsing Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 14.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-024000-10-BEBiogen Idec Limited300
进行中（未招募）
不适用
A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple SclerosisRelapsing-Remitting Multiple SclerosisEUCTR2010-024000-10-ITBIOGEN IDEC LTD300